Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis.


Journal

Journal of child neurology
ISSN: 1708-8283
Titre abrégé: J Child Neurol
Pays: United States
ID NLM: 8606714

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 23 11 2018
medline: 18 3 2020
entrez: 23 11 2018
Statut: ppublish

Résumé

Efferent visual dysfunction in children could lead to impaired quality of life at home and school. Eye-tracking can detect subtle efferent dysfunction missed on bedside examination but has not been validated in the pediatric multiple sclerosis population. We sought to determine the feasibility of eye-tracking in children and associations with multiple sclerosis. Participants meeting criteria for pediatric multiple sclerosis without acute efferent vision abnormalities and healthy controls were recruited. Multiple sclerosis participants underwent a clinical assessment and saccade and antisaccade testing paradigms. Intraclass correlation coefficients were generated for intertest repeatability. Adjusting for age and intereye correlations, generalized estimating equations compared latencies with case status, Expanded Disability Status Scale and Symbol Digit Modalities Test (SDMT) scores. We eye-tracked 15 children with multiple sclerosis (n = 30 eyes, mean age 15.6 ± 2.1, mean disease duration 3.9 years, median Expanded Disability Status Scale 1.5) compared to 6 healthy controls (n = 12 eyes, age 14.3 ± .95). The intraclass correlation coefficient for repeated trials was 0.85. Adjusting for age, saccadic latency was 60 milliseconds (ms) longer for cases than controls (95% confidence interval = 26.4, 93.8; P = .0005). For antisaccadic latency, we observed a similar trend of 60 ms longer for cases than controls ( P = .06). Eye-tracking is a short noninvasive examination, and high intertest repeatability supports use of eye-tracking technology in pediatric multiple sclerosis. Longer saccadic latencies were seen in children with multiple sclerosis despite short disease duration and low Expanded Disability Status Scale scores.

Sections du résumé

BACKGROUND
Efferent visual dysfunction in children could lead to impaired quality of life at home and school. Eye-tracking can detect subtle efferent dysfunction missed on bedside examination but has not been validated in the pediatric multiple sclerosis population.
OBJECTIVE
We sought to determine the feasibility of eye-tracking in children and associations with multiple sclerosis.
METHODS
Participants meeting criteria for pediatric multiple sclerosis without acute efferent vision abnormalities and healthy controls were recruited. Multiple sclerosis participants underwent a clinical assessment and saccade and antisaccade testing paradigms. Intraclass correlation coefficients were generated for intertest repeatability. Adjusting for age and intereye correlations, generalized estimating equations compared latencies with case status, Expanded Disability Status Scale and Symbol Digit Modalities Test (SDMT) scores.
RESULTS
We eye-tracked 15 children with multiple sclerosis (n = 30 eyes, mean age 15.6 ± 2.1, mean disease duration 3.9 years, median Expanded Disability Status Scale 1.5) compared to 6 healthy controls (n = 12 eyes, age 14.3 ± .95). The intraclass correlation coefficient for repeated trials was 0.85. Adjusting for age, saccadic latency was 60 milliseconds (ms) longer for cases than controls (95% confidence interval = 26.4, 93.8; P = .0005). For antisaccadic latency, we observed a similar trend of 60 ms longer for cases than controls ( P = .06).
CONCLUSION
Eye-tracking is a short noninvasive examination, and high intertest repeatability supports use of eye-tracking technology in pediatric multiple sclerosis. Longer saccadic latencies were seen in children with multiple sclerosis despite short disease duration and low Expanded Disability Status Scale scores.

Identifiants

pubmed: 30463467
doi: 10.1177/0883073818807787
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-43

Auteurs

Andrew Yousef (A)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Michael Devereux (M)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Pierre-Antoine Gourraud (PA)

2 Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, Nantes, France.
3 CHU de Nantes, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, France.

Soren Jonzzon (S)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Leena Suleiman (L)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Emmanuelle Waubant (E)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Ari Green (A)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Jennifer S Graves (JS)

1 Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
4 Department of Neuroscience, University of California San Diego, San Diego, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH